When it comes to supply disruptions in medical device manufacturing, unit price never tells the full story. A roll of tape or a cartridge of adhesive may cost only a few dollars. But when it becomes unavailable, the resulting disruption can cost a manufacturer tens or even hundreds of thousands of dollars.  

The Real Cost of Disruption 

What may not be factored into a material choice is the production downtime, engineering work, quality validation, supplier audits, operator retraining, updated documentation and potential regulatory review required to approve a replacement.  

Even a minor shortage or product change can delay a device build, put customer commitments at risk and consume months of work across procurement, operations, engineering and quality. 

“When procurement teams are quantifying the piece price of a product, they’re not necessarily quantifying the burden rate of this whole process,” said R.S. Hughes National Accounts Business Manager Kathleen Westmoreland. “The cost can be underestimated and oftentimes unknown. It can add up to tens or hundreds of thousands of dollars.”  

Westmoreland recently saw how a packaging change could threaten production. When a supplier stopped shrink-wrapping the material used in clean rooms, the change could have caused a work stoppage without an inventory buffer, leading to a reversal of the decision by the manufacturer of the material.   

“It highlights how even such a small change can have a huge impact,” Westmoreland emphasized. 

Evaluating supply risk based on unit price alone creates a blind spot that is compounded by having too many suppliers.  

Supplier Complexity Compounds Risk 

Each distributor brings its own lead times, minimum order quantities, shipping schedules, quality records and documentation requirements. Adding or replacing one is not simply a purchasing decision. It is a quality-system event that may require audits, requalification and updated records tied to each lot. 

When a supplier reformulates or discontinues a material, the downstream consequences can include requalification, biocompatibility retesting and regulatory filings with FDA or a notified body—a process that compounds with every additional supplier relationship a manufacturer maintains. 

“A device BOM spans adhesives, tapes, films and converted parts,” said Craig Legleiter, National Accounts Business Manager at R.S. Hughes. “A gap in any one halts the build. The weakest supplier sets the reliability of the whole line.” 

“Risk isn’t additive, it’s multiplicative,” Legleiter said. “Each added supplier multiplies the coordination surface and the odds that something, somewhere, slips at the wrong moment.” 

What Consolidation Looks Like 

Manufacturers can reduce that exposure by building deeper relationships with fewer capable partners that provide visibility, technical support and a coordinated response when conditions change.   

That relationship may include forecast collaboration, safety-stock agreements, shelf-life monitoring, documented cost savings and regular business reviews. It also means having named contacts who understand the requirements of each manufacturing facility, supported by dedicated customer care, inventory and quality teams. 

“The stronger the partnership, the better positioned the medical device manufacturer is to absorb a supply disruption,” Westmoreland said. 

In practice, consolidation can also reduce the amount of processing and documentation work performed inside the plant. R.S. Hughes provides reliable distribution, integrated supply solutions and engineered converting through Saunders by R.S. Hughes—all backed by technical expertise and scalable service.  

R.S. Hughes operates over 40 distribution centers across the U.S., Mexico and Costa Rica, positioning inventory closer to customer manufacturing facilities. Combined with teams monitoring forecasts, shelf life and supply conditions, consolidation gives manufacturers greater visibility, fewer handoffs and more time to respond before a supply issue reaches the production line.